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ABSTRACT. Simulation experimental ADMA-like preeclampsia was carried out by administering 
the rats with L-NAME during 14-20 days of pregnancy. In animals, there was an increase in blood 
pressure, proteinuria, impaired microcirculation in the placenta, the violation of the regulation of 
vascular tone and destructive changes in the ischemic placenta. The use of phosphodiesterase 5 and 
selective inhibitor of arginase II ZB49-0010 leads to the expression of morphological and functional 
correction of violations occurring in modeling of experimental preeclampsia. 
Keywords: rats; N-nitro-L-arginine methyl ester; endothelial dysfunction; preeclampsia; 
phosphodiesterase 5; a selective inhibitor of arginase II.  
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Аннотация: Моделирование экспериментального ADMA-подобного гестоза осуществляли путем 
введения крысам L-NAME с 14 по 20 сутки беременности. У животных наблюдалось повышение 
артериального давления, протеинурия, нарушение микроциркуляции в плаценте, нарушение 
регуляции сосудистого тонуса и деструктивные изменения в плаценте ишемического генеза. 
Использование тетрагидробиоптерина и селективного ингибитора аргиназы II ZB49 -0010 
приводило к выраженной коррекции морфофункциональных нарушений возникающих при 
моделировании экспериментального гестоза. Таким образом, результаты проведенного 
эксперимента дают основания для продолжения поиска препаратов с эндотелеопротестивными 
свойствами с целью коррекции гестоза. 
Ключевые слова: крысы, N-нитро-L-аргинин-метиловый эфир, дисфункция эндотелия, 
экспериментальный гестоз, тетрагидробиоптерин, селективный ингибитор аргиназы II.  
INTRODUCTION. Preeclampsia is the most 
common disease of pregnant women and ranks first 
in causes of maternal and perinatal mortality. 
Recently, many authors have plyed a significant 
role in the pathogenesis of the disease is removed 
endothelial dysfunction [1, 2]. The increased levels 
of free radicals, hormones, growth factors, pro-
inflammatory cytokines, antigens of the fetus and 
other humoral factors causing increase of cell 
adhesion molecules, and the accumulation of 
endogenous inhibitors of eNOS-methylated 
analogs of L-arginine asymmetric dimethylarginine 
(ADMA) and monometilarginina (L-NMMA), 
which are predictors of preeclampsia [3, 4, 5].  
MAIN PART. In this regard, the current 
research seems to influence phosphodiesterase 5 
and selective inhibitor of arginase II ZB49-0010, 
on for ADMA-like experimental preeclampsia. 
PROCEDURE.  The experiment was 
performed on 40 female white rats of Wistar strain 
weighing 250-300 g with a ADMA-similar agent – 
a non-selective NO-synthase blocker of N-nitro-L-
arginine methyl ester (L-NAME) was administered 
intraperitoneally in a dose of 25 mg / kg / daily for 
seven days (day 14-20 of pregnancy). The 
endothelial dysfunction was assessed by the ratio 
of endothelium and vascular endothelium reactions 
to the calculation of the coefficient of endothelial 
dysfunction (CED) [6, 7, 8, 9]. Pregnant females 
were divided into groups (n = 10): I – intact; II – 
with L-NAME administration daily from the 14th 
to the 21st day of pregnancy; III – the introduction 
of L-NAME + phosphodiesterase 5 (0,9 mg / kg); 
IV – with the introduction of L-NAME + selective 
inhibitor of arginase II ZB49-0010. 
Microcirculation Research carried on the outer 
surface of the uterine horn at a distance of 1 mm 
from the visible edge of the placental disc. 
FINDINGS OF THE STUDY. The blockade 
of NO-synthase caused by the seven-day 
administration of L-NAME led to a breach of the 
relationship of the vasoconstrictor and vasodilating 
mechanisms of regulation of vascular tone, as 
evidenced by the increase in QED with 1,1 ± 0,11 
intact pregnant animals to 3,12 ± 0,17 ( p <0.05). 
In addition, there was a significant rise in systolic 
and diastolic blood pressure 134,5 ± 2,3 and 92,0 ± 
2,1 to 186,3 ± 6,9 and 143,1 ± 4,2 mm Hg. Art. 
respectively. The introduction of the blocker NO-
synthase resulted in a significant reduction in the 
microcirculation of the placenta index with 446.3 ± 
27.5 to 218.3 ± 13,67 (p <0.05), as well as in the 
reduction of the NOx content of the stable 
metabolite in serum 2 28 ± 0,11 mmol / dL to 
mmol 1,28 ± 0,08 / dl (p <0.05).  
Application of phosphodiesterase 5 and 
selective inhibitor of arginase II ZB49 = 0010 led 
to the normalization of relations between the 
vasodilating and vasoconstrictor response in 
experimental pre-eclampsia, as evidenced by the 
decline and statistically significant (p <0.05) 
decrease in blood pressure (Table. 1). In addition, 
there was an improvement of microcirculation in 
the placenta. 
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Table 1 
Results of correction of ADMA-like preeclampsia in rats (M ± m) 
Index 








nitrite ions (NOx), 
μmol/l 
Intact animals 134,5±2,3y 92,0±2,1y 1,10±0,11y 446,3±27,46y 2,28±0,11y 
L-NAME 186,3±6,9* 143,1±4,2* 3,12±0,17* 218,3±13,67* 1,28±0,08y 
L-NAME + FDE 5 149,7±2,2* 97,6±3,2* 1,85±0,08 y 398.7±24,84 y 1,36±0,1у 
L-NAME + ZB49-0010 162,5±8,7* 130,2±6,7* 1,49±0,14y 435,4±27,35y 1,95±0,06y 
Note: SBP, DBP – systolic and diastolic blood pressure (mmHg.); CED – the coefficient of endothelial dysfunction (conv.); 
microcirculation in the placenta (PU); the concentration of nitrite ion (NOx); * – P <0.05 compared to the group of intact animals; y- P <0.05 
compared with the group of L-NAME. 
When blood serum biochemical study found a 
statistically significant reduction of the prevention of 
stable metabolites of NO, the level of which amounted 
to 1,86 ± 0,07 mmol / dl and 1,95 ± 0,06 mmol / dL, 
respectively. 
The efficiency of use of FDE 5 can be explained 
by the inhibition of phosphodiesterase 5 in the 
endothelia and an increase by the maintenance of cyclic 
adenosine monophosphate. 
The mechanism of action of the selective inhibitor 
of arginase II ZB49-0010 its inhibitory effects on 
arginase 2. Given that eNOS and arginase compete for 
common substrate, increases the possibility of using L-
arginine for NO synthesis [10, 11, 12, 13]. 
Ultimately, the mechanism of action of both drugs 
is reduced to restore the NO-synthesis function and to 
reduce the endothelial dysfunction. The differences in 
their endothelioprotective effects explain the different 
points of application in the pathway L-Arginine – NO. 
CONCLUSION. Thus, the results of this 
experiment provide a basis for further research in order 
to find drugs with activity endoteleoprotestivnoy 
correction of preeclampsia. 
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